lomefloxacin has been researched along with Bacterial Disease in 20 studies
lomefloxacin: structure given in first source
lomefloxacin : A fluoroquinolone antibiotic, used (generally as the hydrochloride salt) to treat bacterial infections including bronchitis and urinary tract infections. It is also used to prevent urinary tract infections prior to surgery.
| Excerpt | Relevance | Reference |
|---|---|---|
| "5% in the lomefloxacin group and from 94% to zero in the chloramphenicol group; rates of hyperemia decreased from 100% to zero in both groups." | 9.13 | Postoperative lomefloxacin 0.3% prophylaxis in strabismus surgery. ( Axer-Siegel, R; Bagan, J; Ehrlich, R; Friling, R; Goldenberg-Cohen, N; Hasanreisoglu, M; Snir, M, 2008) |
| "The clinical efficacy, safety and usefulness of lomefloxacin (LFLX, NY-198), a new quinolone antimicrobial agent, were compared with those of pipemidic acid (PPA) in the treatment of infectious enteritis (bacillary dysentery, enteropathogenic Escherichia coli enteritis and Campylobacter enteritis) by a double blind method." | 9.06 | [Comparison of clinical efficacy of lomefloxacin (LFLX, NY-198) and pipemidic acid (PPA) in the treatment of infectious enteritis by a double-blind method. The Japan Research Committee of Lomefloxacin Research Group Enteritis]. ( Aoki, T; Kanehisa, N; Matsubara, Y; Murata, M; Nitta, Y; Sagara, H; Seo, T; Shimizu, N; Takizawa, Y; Tomizawa, I, 1989) |
| "5% in the lomefloxacin group and from 94% to zero in the chloramphenicol group; rates of hyperemia decreased from 100% to zero in both groups." | 5.13 | Postoperative lomefloxacin 0.3% prophylaxis in strabismus surgery. ( Axer-Siegel, R; Bagan, J; Ehrlich, R; Friling, R; Goldenberg-Cohen, N; Hasanreisoglu, M; Snir, M, 2008) |
| "The clinical efficacy, safety and usefulness of lomefloxacin (LFLX, NY-198), a new quinolone antimicrobial agent, were compared with those of pipemidic acid (PPA) in the treatment of infectious enteritis (bacillary dysentery, enteropathogenic Escherichia coli enteritis and Campylobacter enteritis) by a double blind method." | 5.06 | [Comparison of clinical efficacy of lomefloxacin (LFLX, NY-198) and pipemidic acid (PPA) in the treatment of infectious enteritis by a double-blind method. The Japan Research Committee of Lomefloxacin Research Group Enteritis]. ( Aoki, T; Kanehisa, N; Matsubara, Y; Murata, M; Nitta, Y; Sagara, H; Seo, T; Shimizu, N; Takizawa, Y; Tomizawa, I, 1989) |
| "Results of trials of lomefloxacin (400 mg once daily) in elderly patients with uncomplicated urinary tract infections, complicated urinary tract infections, acute bacterial exacerbations of chronic bronchitis, and as prophylaxis for transurethral surgical procedures (400 mg single dose) have been analyzed." | 4.78 | Infection in the elderly: studies with lomefloxacin. ( Bruce-Jones, P; Crome, P, 1992) |
| "Lomefloxacin is a new fluoroquinolone antimicrobial agent that has undergone extensive worldwide clinical evaluation." | 2.38 | The U.S. clinical experience with lomefloxacin, a new once-daily fluoroquinolone. ( Rizk, E, 1992) |
| "Lomefloxacin is a new oral fluoroquinolone that is indicated for the treatment of various bacterial infections." | 2.38 | Lomefloxacin and temafloxacin: two new fluoroquinolone antimicrobials. ( Nix, DE; Symonds, WT, 1992) |
| " Lomefloxacin offers certain advantages compared with other quinolone antibacterial drugs in that it may be conveniently administered once daily and theophylline dosage adjustment does not appear to be necessary in patients receiving this bronchodilator concomitantly." | 2.38 | Lomefloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. ( Goa, KL; Wadworth, AN, 1991) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 8 (40.00) | 18.7374 |
| 1990's | 10 (50.00) | 18.2507 |
| 2000's | 2 (10.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Domagala, JM | 1 |
| Bridges, AJ | 1 |
| Culbertson, TP | 1 |
| Gambino, L | 1 |
| Hagen, SE | 1 |
| Karrick, G | 1 |
| Porter, K | 1 |
| Sanchez, JP | 1 |
| Sesnie, JA | 1 |
| Spense, FG | 1 |
| Snir, M | 1 |
| Hasanreisoglu, M | 1 |
| Friling, R | 1 |
| Goldenberg-Cohen, N | 1 |
| Ehrlich, R | 1 |
| Bagan, J | 1 |
| Axer-Siegel, R | 1 |
| Jones, RN | 1 |
| Rossolini, GM | 1 |
| Valentini, S | 1 |
| Vaiani, G | 2 |
| Satta, G | 1 |
| Cuffini, AM | 1 |
| Tullio, V | 1 |
| Carlone, NA | 1 |
| Suzuki, T | 1 |
| Sasada, M | 1 |
| Okuma, M | 1 |
| Fukuhara, S | 1 |
| Yasuda, N | 1 |
| Amano, H | 1 |
| Kanachi, K | 1 |
| Ohno, T | 1 |
| Kawasaki, T | 1 |
| Yumoto, Y | 1 |
| Kim, JH | 2 |
| Kang, JA | 1 |
| Kim, YG | 1 |
| Kim, JW | 2 |
| Lee, JH | 2 |
| Choi, EC | 2 |
| Kim, BK | 2 |
| Choi, KH | 1 |
| Padeĭskaia, EN | 1 |
| Crome, P | 1 |
| Bruce-Jones, P | 1 |
| Rizk, E | 1 |
| Symonds, WT | 1 |
| Nix, DE | 1 |
| Soejima, R | 1 |
| Matsumoto, F | 1 |
| Wadworth, AN | 1 |
| Goa, KL | 1 |
| Aoki, T | 1 |
| Shimizu, N | 1 |
| Tomizawa, I | 1 |
| Takizawa, Y | 1 |
| Matsubara, Y | 1 |
| Nitta, Y | 1 |
| Sagara, H | 1 |
| Seo, T | 1 |
| Kanehisa, N | 1 |
| Murata, M | 1 |
| Ono, Y | 1 |
| Kunii, O | 1 |
| Edwards, R | 1 |
| Kanematsu, M | 1 |
| Greenwood, D | 1 |
| Tanimura, H | 1 |
| Aoki, Y | 1 |
| Uesaka, K | 1 |
| Kasano, Y | 1 |
| Nakai, T | 1 |
| Kitamura, T | 1 |
| Mukaihara, S | 1 |
| Tamura, K | 1 |
| Yotsumoto, F | 1 |
| Terao, R | 1 |
| Hirose, T | 1 |
| Okezaki, E | 1 |
| Kato, H | 1 |
| Ito, Y | 1 |
| Inoue, M | 1 |
| Mitsuhashi, S | 1 |
6 reviews available for lomefloxacin and Bacterial Disease
| Article | Year |
|---|---|
[A broad-spectrum antimicrobial preparation--lomefloxacin (Maxaquin): the results of 10 years of its use in the clinics of Russia].
Topics: Anti-Infective Agents; Anti-Infective Agents, Urinary; Antitubercular Agents; Bacterial Infections; | 2000 |
Infection in the elderly: studies with lomefloxacin.
Topics: Aged; Aging; Anti-Infective Agents; Bacterial Infections; Bronchitis; Female; Fluoroquinolones; Huma | 1992 |
The U.S. clinical experience with lomefloxacin, a new once-daily fluoroquinolone.
Topics: Anti-Infective Agents; Bacterial Infections; Bronchitis; Fluoroquinolones; Humans; Meta-Analysis as | 1992 |
Lomefloxacin and temafloxacin: two new fluoroquinolone antimicrobials.
Topics: Anti-Infective Agents; Bacteria; Bacterial Infections; Drug Interactions; Drug Resistance, Microbial | 1992 |
[Review [new antimicrobial agent series XLI]: lomefloxacin].
Topics: Animals; Anti-Infective Agents; Bacteria; Bacterial Infections; Drug Evaluation; Drug Resistance, Mi | 1991 |
Lomefloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.
Topics: Animals; Anti-Infective Agents; Bacteria; Bacterial Infections; Drug Interactions; Fluoroquinolones; | 1991 |
3 trials available for lomefloxacin and Bacterial Disease
| Article | Year |
|---|---|
Postoperative lomefloxacin 0.3% prophylaxis in strabismus surgery.
Topics: Administration, Topical; Adolescent; Adult; Aged; Anti-Infective Agents; Bacterial Infections; Child | 2008 |
[Clinical efficacy of lomefloxacin for associated infection in patients with hematological diseases].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Bacterial Infections; Female; Flu | 1997 |
[Comparison of clinical efficacy of lomefloxacin (LFLX, NY-198) and pipemidic acid (PPA) in the treatment of infectious enteritis by a double-blind method. The Japan Research Committee of Lomefloxacin Research Group Enteritis].
Topics: 4-Quinolones; Adolescent; Adult; Aged; Anti-Infective Agents; Bacterial Infections; Double-Blind Met | 1989 |
11 other studies available for lomefloxacin and Bacterial Disease
| Article | Year |
|---|---|
Synthesis and biological activity of 5-amino- and 5-hydroxyquinolones, and the overwhelming influence of the remote N1-substituent in determining the structure-activity relationship.
Topics: Alkylation; Aminoquinolines; Animals; Anti-Bacterial Agents; Bacterial Infections; Chemical Phenomen | 1991 |
In vitro evaluation of lomefloxacin (NY-198 or SC-47111), a new difluoro-quinolone.
Topics: Anti-Infective Agents; Bacteria; Bacterial Infections; Fluoroquinolones; Humans; Microbial Sensitivi | 1989 |
In vitro antimicrobial activity of lomefloxacin against staphylococci, enterococci, and Enterobacteriaceae.
Topics: Anti-Infective Agents; Bacterial Infections; Enterobacteriaceae; Enterococcus; Fluoroquinolones; Hum | 1989 |
Comparison of the antibacterial activity of lomefloxacin with that of other antibiotic/chemotherapeutic agents.
Topics: Anti-Bacterial Agents; Bacterial Infections; Fluoroquinolones; Gram-Negative Bacteria; Gram-Positive | 1989 |
In vitro and in vivo antibacterial efficacies of CFC-222, a new fluoroquinolone.
Topics: Animals; Anti-Infective Agents; Bacteria; Bacterial Infections; Ciprofloxacin; Culture Media; Fluoro | 1997 |
In-vitro and in-vivo antibacterial activity of CFC-222, a new fluoroquinolone.
Topics: Animals; Anti-Infective Agents; Bacterial Infections; Ciprofloxacin; Fluoroquinolones; Male; Mice; M | 1998 |
Lomefloxacin reaches U.S. market.
Topics: Anti-Infective Agents; Bacterial Infections; Fluoroquinolones; Humans; Quinolones; United States; Un | 1992 |
[Studies of lomefloxacin in biliary tract infections].
Topics: 4-Quinolones; Adult; Aged; Anti-Infective Agents; Bacteria; Bacterial Infections; Biliary Tract Dise | 1989 |
Laboratory assessment of lomefloxacin (SC-47111) in comparison with norfloxacin.
Topics: Anti-Bacterial Agents; Bacteria; Bacterial Infections; Fluoroquinolones; Humans; Microbial Sensitivi | 1988 |
[Chemotherapy for biliary tract infection (XXXIII). Tissue concentration of NY-198 in gallbladder, biliary excretion and clinical effects].
Topics: Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Bacterial Infections; Bile; Cholangitis; Chol | 1988 |
In vitro and in vivo activity of NY-198, a new difluorinated quinolone.
Topics: Animals; Anti-Infective Agents; Bacterial Infections; Fluoroquinolones; Male; Mice; Microbial Sensit | 1987 |